Category : Healthcare and Pharmaceuticals | Published at : January-2021 | Delivery Format : PDF | Status: Published | Pages : 190
The market for orthobiologics is expected to grow at a CAGR of around 5.6% from 2020 to 2027 and expected to reach the market value of around US$ 7,725.6 Mn by 2027.
Orthobiologics are biological substances that help in quick heal of musculoskeletal injuries like fractures, injured muscles, tendons, and ligaments. These are made from the natural substances that occur in the body. The bone grafts, autologous blood, autologous conditioned serum, platelet-rich plasma, growth factors, and stem cells are considered as orthobiologics. Orthobiologics are used for the treatment associated with the knee, hip, ankle, spine, wrist, and other body parts.
Market Dynamics
The increasing incidence of sports injuries & road accidents, as well as increasing incidence of spinal diseases/disorders, are boosting the market value. The rising geriatric & obese population and growing patient preference for minimally invasive procedures in emerging markets is accelerating the market value. The emerging markets along with the rapid urbanization are projected to create potential opportunities over the forecast period from 2020 to 2027.
On the other side, high cost associated with orthobiologics-based treatments, post-surgery complications, and stringent regulatory approval is likely to hinder the growth to an extent over the estimated timeframe from 2020 to 2027.
Viscosupplementation Products is dominating the global Orthobiologics Market
By product, viscosupplementation products are the leading segment in the global market. The better reimbursement scenarios for the products in some economies like France are supporting the segmental market value. The approval for the use by the U.S. Food and Drug Administration (FDA) is additionally contributing to the segmental market value. Furthermore, the growing prevalence of lifestyle-induced disorders such as obesity is bolstering the segmental market value. The viscosupplementation products segment is also projected to exhibit the fastest growth with major CAGR (%) over the estimated period from 2020 to 2027.
North America registered maximum revenue share in the Orthobiologics Market
In 2019, North America was leading the global orthobiologics market owing to its advanced healthcare infrastructure. The rapidly growing geriatric population in the region is supporting the regional market value. The major economies of the region including the US and Canada are contributing to the regional market value. The increasing incidence of spinal disorders, growing physician, and patient awareness about newly introduced treatment procedures and technologies are propelling the regional market value. The consistent efforts made by industry players in promoting awareness associated with the orthobiological products are further bolstering the regional market value. The presence of major players in the region such as Globus Medical, Inc, Johnson and Johnson (J&J), and Medline Industries, Inc. among others is further supporting the regional market value. Moreover, Asia Pacific is anticipated to exhibit the fastest growth over the estimated period from 2020 to 2027. The rapidly developing countries including India and China are accelerating the regional market value. The increasing disposable income and rising investment by the government and industry players for the development of healthcare facilities in the region are additionally bolstering the regional market value.
The players profiled in the report include Arthrex, Inc. (Arthrex), Exactec Inc., Globus Medical, Inc., Integra LifeSciences Holdings Corporation, Johnson and Johnson (J&J), Medline Industries, Inc., NuVasive Inc., Stryker Corporation, Wright Medical Group, Inc., and Zimmer Biomet Holdings, Inc. The major orthobiologics players were involved in strategic developments for escalating the profit share in regional as well as global market. The major investments were announced for the technological advancements associated with the changing consumer demand for orthobiologics
Market Segmentation
Market By Product
Demineralized Bone Matrix (DBM)
Allograft
Bone Morphogenetic Protein (BMP)
Viscosupplementation Products
Synthetic Bone Substitutes
Others
Market By Application
Osteoarthritis and Degenerative Arthritis
Spinal Fusion
Fracture Recovery
Soft Tissue Injuries
Maxillofacial and Dental Applications
Market By End User
Hospitals, Orthopedic Clinics, and Ambulatory Care Centers
Research and Academic Institutes
Dental Clinics and Facilities
Market By Geography
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Frequently Asked Questions
The market for orthobiologics is expected to reach a market value of around US$ 7,725.6 Mn by 2027.
The orthobiologics market is expected to grow at a CAGR of around 5.6% from 2020 to 2027.
The viscosupplementation product is the leading segment by product in the orthobiologics market.
The increasing incidence of sports injuries & road accidents, increasing incidence of spinal diseases/disorders, rising geriatric & obese population, and growing patient preference for minimally invasive procedures are some of the prominent factors driving the market growth.
Arthrex, Inc. (Arthrex), Exactec Inc., Globus Medical, Inc., Integra LifeSciences Holdings Corporation, Johnson and Johnson (J&J), Medline Industries, Inc., NuVasive Inc., Stryker Corporation, Wright Medical Group, Inc., and Zimmer Biomet Holdings, Inc. are the prominent players in the market.
North America held the highest market share in the orthobiologics market.
Asia Pacific is expected to be the fastest growing market over the forecast period.
